SkinBioTherapeutics ( (GB:SBTX) ) has issued an announcement.
SkinBioTherapeutics announced that Croda plc has launched Zenakine™, a neuroactive ingredient designed to improve skin health by reducing stress effects and enhancing sleep quality, at the in-cosmetics Global exhibition. This launch marks a significant milestone for SkinBioTherapeutics, as Zenakine™ is the first ingredient with clinical measures on sleep benefits, offering a competitive edge in the cosmetics industry with its multifunctional and sustainable formulation options.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.
SkinBioTherapeutics shows promise with recent revenue growth and strategic acquisitions. However, significant financial challenges remain due to ongoing losses and negative cash flow. The stock’s technical indicators suggest positive momentum, while corporate events highlight potential market expansion. The valuation remains a concern due to the negative P/E ratio.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a life science company focused on skin health, utilizing its proprietary platform technology, SkinBiotix®, developed from research at the University of Manchester. The company targets the skin healthcare market through five pillars, including cosmetic skincare and food supplements, with partnerships such as the one with Croda plc. It also engages in acquisitions to expand its distribution and manufacturing capabilities.
YTD Price Performance: 35.14%
Average Trading Volume: 883,228
Technical Sentiment Signal: Strong Sell
Current Market Cap: £55.09M
See more data about SBTX stock on TipRanks’ Stock Analysis page.